stockrowADMA Biologics Inc
ADMA Healthcare Biotechnology
ADMA Biologics Inc’s revenue for fiscal 2025 (year ended December 2025) was $510.2 million, up 19.6% from fiscal 2024.
- Revenue
- +5.12%
- EPS
- +46.7%
- Free cash flow
- +1,709.5%
- Total debt
- +140.5%
Quarter to September 2026, against a year earlier
Follow ADMA
Alert me
ADMA Biologics Inc (ADMA) Return on assets
ADMA Biologics Inc's return on assets over the twelve months to 30 September 2026 was 28.0%, up 1.6 percentage points from fiscal 2025 (26.4%). Over the past ten years it has ranged from −82.3% (fiscal 2016) to 48.3% (fiscal 2024); the current reading is higher than 91% of that period. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 26.4% | (21.94) |
| FY2024 | 48.3% | 56.67 |
| FY2023 | −8.33% | 12.77 |
| FY2022 | −21.1% | 8.51 |
| FY2021 | −29.6% | 15.64 |
| FY2020 | −45.3% | (0.54) |
| FY2019 | −44.7% | 22.07 |
| FY2018 | −66.8% | (0.33) |
| FY2017 | −66.5% | 15.89 |
| FY2016 | −82.3% | (11.51) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | 46.5% |
| ADMA ADMA Biologics Inc | 28.0% |
| VCEL Vericel Corporation compare | 6.86% |
| PVLA Palvella Therapeutics, Inc. compare | −37.7% |
| CLDX Celldex Therapeutics, Inc. compare | −40.8% |
| IMNM Immunome, Inc. compare | −59.0% |
| PHVS Pharvaris N.V. compare | −64.4% |
| VERA Vera Therapeutics, Inc. compare | −72.3% |
| BHVN Biohaven Ltd. compare | −161.3% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on ADMA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement